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Aims The deacetylase sirtuin1 (Sirt1) exertsbeneficial effects on lipidmetabolism, but its roles in plasma LDL-cholesterol regu-
lation and atherosclerosis are controversial. Thus, we applied the pharmacological Sirt1 activator SRT3025 in a mouse
model of atherosclerosis and in hepatocyte culture.
Methods
and results
Apolipoprotein E-deficient (Apoe2/2) mice were fed a high-cholesterol diet (1.25% w/w) supplemented with SRT3025
(3.18 g kg21 diet) for 12 weeks. In vitro, the drug activated wild-type Sirt1 protein, but not the activation-resistant
Sirt1 mutant; in vivo, it increased deacetylation of hepatic p65 and skeletal muscle Foxo1. SRT3025 treatment decreased
plasma levels of LDL-cholesterol and total cholesterol and reduced atherosclerosis. Drug treatment did not change
mRNA expression of hepatic LDL receptor (Ldlr) and proprotein convertase subtilisin/kexin type 9 (Pcsk9), but
increased their protein expression indicating post-translational effects. Consistent with hepatocyte Ldlr and Pcsk9 accu-
mulation, we found reduced plasma levels of Pcsk9 after pharmacological Sirt1 activation. In vitro administration of
SRT3025 to cultured AML12 hepatocytes attenuated Pcsk9 secretion and its binding to Ldlr, thereby reducing Pcsk9-
mediated Ldlr degradation and increasing Ldlr expression and LDL uptake. Co-administration of exogenous Pcsk9
with SRT3025 blunted these effects. Sirt1 activation with SRT3025 in Ldlr2/2 mice reduced neither plasma Pcsk9, nor
LDL-cholesterol levels, nor atherosclerosis.
Conclusion We identify reduction in Pcsk9 secretion as a novel effect of Sirt1 activity and uncover Ldlr as a prerequisite for Sirt1-
mediated atheroprotection in mice. Pharmacological activation of Sirt1 appears promising to be tested in patients for
its effects on plasma Pcsk9, LDL-cholesterol, and atherosclerosis.
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Translational perspective
The deacetylase Sirt1 exerts beneficial effects on metabolic and inflammatory diseases. However, its effects on lipid metabolism and athero-
sclerosis remain controversial. Lowering plasma Pcsk9 emerges as a promising therapeutic strategy to lower plasma LDL-cholesterol. Unlike
current antibody-based strategies that act on extracellular Pcsk9 activity, we found an alternative route to decrease Pcsk9-mediated Ldlr deg-
radation: pharmacological Sirt1 activation reduced hepatic Pcsk9 secretion, increased Ldlr expression, and decreased plasmaLDL-cholesterol
and atherosclerosis in mice. Thus, Sirt1 activation appears as a promising approach to be tested for atheroprotection in patients.
Introduction
Atherosclerosis results from acomplex interplaybetween innate and
adaptive immunity involving modified LDL-cholesterol, activated
endothelial cells, and monocyte-derived macrophages within the ar-
terial wall. Sirt1 is amemberof the sirtuin familyof NAD+-dependent
deacetylases.1 Studies on the role of Sirt1 in atherosclerosis have
reported controversial effects.
Sirt1 has been shown to be atheroprotective in apolipoprotein
E-deficient (Apoe2/2) mice2 –4 whereas genetic overexpression of
Sirt1 in LDL-receptor-deficient (Ldlr2/2) mice enhanced athero-
sclerosis.5 The role of Sirt1 in regulation of plasma LDL-cholesterol
concentration, the key trigger of atherogenesis,6 remains in-
completely understood. Hepatic deletion of Sirt1 in C57BL/6 mice
fed a high-cholesterol diet induced mild hypercholesterolemia.7
Conversely, administration of a Sirt1 activating drug to elderly vol-
unteers and cigarette smokers decreased plasma levels of total and
LDL-cholesterol.8,9 These studies suggest that Sirt1 regulates
plasma LDL-cholesterol.
Hepatic Ldlr clears LDL-cholesterol from the blood stream.10,11
Transcription of Ldlr is controlled by the sterol-responsive
element binding protein 2 (Srebp2),12 while its turnover depends
on proprotein convertase subtilisin/kexin type 9 (Pcsk9), a serine
protease.13 SecretedPcsk9 targets hepaticLdlr for lysosomal degrad-
ation and thus prevents recycling of internalized Ldlr to the cell
surface.14
We hypothesized that hepatic Ldlr mediates the effects of Sirt1
on plasma LDL-cholesterol levels and thus provides atheroprotec-
tion. To test this hypothesis, we fed Apoe2/2 or Ldlr2/2 mice a
high-cholesterol diet supplemented with the novel Sirt1 acti-
vator SRT3025 or placebo, and investigated atherogenesis and lipid
metabolism.
Methods
Detailed information is available in Supplementary material online.
Animals
Male Apoe2/2 or Ldlr2/2 mice on a pure C57BL/6J background were
housed with a 12 h light–dark cycle and fed a high-cholesterol diet con-
taining 1.25% cholesterol (D12108; Research Diets) supplemented with
or without (SRT3025, 3.18 g kg21 diet, provided by Sirtris, Cambridge,
MA, USA) for 12weeks starting at the ageof 8 weeks. After this treatment
period, mice were sacrificed (after overnight fasting), EDTA blood was
taken and tissues were harvested. All experiments and animal care pro-
cedures were approved by the local veterinary authorities and carried
out in accordance with our institutional guidelines.
Cell culture
AML12 mouse hepatoma cells were cultured in a 1:1 (v/v) mixture of
DMEM and Ham’s F12 medium supplemented with insulin (5 mg ml21),
transferrin (5 mg ml21), selenium (5 ng ml21), dexamethasone
(40 ng ml21), and 10% FBS (v/v). Where indicated, AML12 cells were
exposed to 10 mM SRT3025 in 1% DMSO (v/v).
Statistics
All data are presented as means+ SD. Data distribution was assessed
using the Kolmogorov–Smirnov test. Normally distributed data were
compared by an unpaired two-tailed Student’s t-test; for non-parametric
data theMann–Whitney testwasused.Threeormoregroups werecom-
pared using a Kruskal–Wallis test followed by a Dunn’s post-hoc com-
parison (non-parametric data). At least three independent experiments
in triplicates were performed. Significance was accepted at P, 0.05.
Analyses were done using Graphpad Prism (version 5.0d, 2010).
Results
SRT3025 reduces plasma cholesterol,
inflammation, and atherosclerosis
in Apoe2/2 mice
Histomorphometry of thoraco-abdominal aortae en face and cross-
sections of aortic roots revealed a significant reduction in plaque size
in SRT3025-treated Apoe2/2 mice compared with placebo-treated
controls (Figure 1A and B). Moreover, a marked reduction of
Cd68-positive macrophages within the plaque and Vcam-1 expres-
sion in aortic roots was observed (Figure 1C and D). Interestingly,
plasma levels of total-, LDL- and VLDL-cholesterol were significantly
lower after SRT3025 treatment compared with placebo (Figure 1E
and F ). Triglycerides and HDL-cholesterol remained unchanged
(Supplementary material online, Figure S1A). In addition, we observed
reduced plasma levels of Mcp-1 and Il-6 (Figure 1G) and lower hepatic
mRNA expression of these cytokines (Figure 3A).
These findings indicate that SRT3025 administration to Apoe2/2
mice provides atheroprotection and reduces plasma LDL-cholesterol
and inflammation.
SRT3025 mimics Sirt1 activity in vitro
and in Apoe2/2 mice
SRT3025 concentration-dependently activated wild-type Sirt1, but
failed to activate the activation-resistant Sirt1 mutant E230K in vitro
(Figure 2A). Increased deacetylation of known Sirt1 targets upon
SRT3025 treatment, hepatic p65 and forkhead transcription factor
family O1 (Foxo1) in skeletal muscle (Figure 2B and C ) indicate suc-
cessful Sirt1 activation in vivo. SRT3025 prevented an increase in
weight gain and epididymal white adipose tissue without affecting
food intake, thereby mimicking a caloric restriction phenotype
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Figure 1 SRT3025 confers atheroprotection, reduces plasma cholesterol and systemic inflammation in Apoe2/2 mice. Eight-week-old Apoe2/2
mice were fed a high-cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12 weeks. Rep-
resentative micrographs (left) and quantifications (right) of thoraco-abdominal aortae en face (A) and of aortic root cross sections (B–D) stainedwith
ORO or immunohistochemically for macrophages (Cd68) or Vcam-1; (E) cholesterol distribution in the different lipoprotein subfractions separated
by gel filtration chromatography; (F ) Plasma total cholesterol, LDL-, and VLDL-cholesterol concentrations; (G) Plasma levels of Mcp-1 and Il-6. Scale
bars inphotomicrographs: 1 mm(A) and 500 mm (B–D). HCD,high-cholesterol diet; AU, arbitraryunits; LDL, low-density lipoprotein;ORO, oil-red
O; VLDL, very low-density lipoprotein; Vcam-1, vascular cell adhesion molecule 1; Mcp-1, monocyte chemoattractant protein 1; Il-6, interleukin 6.
Figure 2 SRT3025 mimics Sirt1 activity in vitro and in Apoe2/2 mice. (A) Concentration-response curve of SRT3025 on the activity of wild-type
Sirt1 and activation-resistant mutant E230K in vitro. (B, C ) Western blots for acetylation status of Sirt1 target proteins (B) p65 and (C) Foxo1 immu-
noprecipitated from nuclear extracts of liver and skeletal muscle, respectively, from Apoe2/2 mice fed a high-cholesterol diet (1.25% w/w) supple-
mented with the Sirt1 activator SRT3025 or placebo for 12 weeks. HCD, high-cholesterol diet; Ac-Ly, anti-acetyl-lysine antibody.
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(Supplementary material online, Figure S1B–D). Pharmacokinetic
analysis of the drug in Apoe2/2 mice showed that the drug indeed
reached target tissues (Supplementary material online, Table S1).
Plasma protein levels of glutamic oxaloacetic transaminase, glutamic
pyruvic transaminase, and alkaline phosphatase were not different
between drug- and placebo-treated mice (Supplementary material
online, Figure S1E).
SRT3025 increases hepatic Ldlr expression
and Pcsk9 accumulation in Apoe2/2 mice
Pharmacological Sirt1 activation increased liver expression of Abca1,
but did not affect Abcg5, Abcg8, Ldlr, Pcsk9, Ppara, Pparg, Srebp1, and
Srebp2 (Figure 3A). Despite no changes in Ldlr and Pcsk9 mRNA
expression, both were markedly increased at the protein level
(Figure 3A and B). This intracellular accumulation of Pcsk9 protein
with no change in mRNA suggests a disturbed transport and/or secre-
tion of the protein. In agreement with this, we found reduced plasma
Pcsk9 protein levels following pharmacological Sirt1 activation in
Apoe2/2 mice compared with placebo-treated controls (Figure 3C).
SRT3025 increases Ldlr expression and
Pcsk9 accumulation in AML12 hepatocytes
To delineate the mechanisms by which SRT3025 affects Ldlr protein
expression, we performed in vitro experiments administering
SRT3025 to mouse hepatoma AML12 cells. We observed a
concentration- and time-dependent increase in Ldlr and Pcsk9
protein expression upon SRT3025 administration in cell lysates
(Figure 4A and B). As observed in vivo, mRNA levels of Ldlr and
Pcsk9 were not altered by SRT3025 (Figure 4C), indicating that post-
translational effects cause the changes in protein expression.
Incubation of AML12 cells with 10 mM SRT3025 was associated
with a time-dependent decrease in Pcsk9 secretion into the super-
natant (Figure 4D). Moreover, co-immunoprecipitation of endogen-
ous Pcsk9 and Ldlr after 24 h incubation with 10 mM SRT3025
revealed that Pcsk9 binding to Ldlr was impaired after SRT3025 treat-
ment compared with vehicle control (Figure 4E). Thus, the question
arises whether the increase in hepatic Ldlr protein expression
upon Sirt1 activation is related to limited extracellular availability of
Pcsk9 and/or a defective degradation of internalized Ldlr.
SRT3025 impairs Pcsk9-dependent
degradation of Ldlr in AML12 hepatocytes
Toaddress theabovequestion,westimulatedAML12cellswith10 mM
SRT3025 for 24 h and compensated for the decrease in extracellular
Pcsk9 by adding exogenous active Pcsk9 protein. Co-administration
of Pcsk9 [3 ng ml21, based upon concentrations measured in the
supernatants of untreated AML12 (Figure 4D)] and SRT3025 to
AML12 hepatocytes attenuated the drug-dependent increase in
Ldlr protein expression (Figure 5A). These data indicate that the in-
ternalization and degradation process of Ldlr is not defective and
that limited extracellular availability of Pcsk9 contributes to the in-
crease in Ldlr protein expression.
Fluorescence analysis revealed an increase in labelled LDL uptake
upon 10 mM SRT3025 treatment compared with vehicle controls
(Figure 5B), suggesting a functional relevance of the SRT3025-
dependent increase in Ldlr expression. Moreover, co-administration
of exogenous active Pcsk9 also attenuated the drug-induced increase
Figure3 SRT3025 increases hepatic Ldlr protein expression while decreasing plasma Pcsk9 in Apoe2/2mice. Eight week-oldApoe2/2micewere
fed a high-cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12 weeks. (A) Relative mRNA
expression levels of hepatic genes involved in cholesterol regulation. (B) Western blots of liver lysates for Ldlr, Pcsk9, andb-actin. (C) Plasma levels
of Pcsk9. HCD, high-cholesterol diet; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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Figure 4 SRT3025 increases Ldlr expression in AML12 hepatocytes and decreases Pcsk9 in the supernatant. Western blots of Ldlr, Pcsk9, and
b-actin in cultured AML12 cells (A) treated with SRT3025 at indicated concentrations for 24 h and (B) incubated with 10 mM SRT3025 for the times
indicated. (C) Relative mRNA expression levels of Ldlr and Pcsk9 in AML12 cells after incubation with 10 mM SRT3025 for 24 h. (D) Pcsk9 protein
levels in the supernatant of AML12 cells incubated with 10 mM SRT3025 for the times indicated. (E) Pcsk9 immunoprecipiated from AML12 cells
incubated with vehicle (Veh, DMSO) or 10 mM SRT3025, and blotted for Ldlr and Pcsk9. Pcsk9, proprotein convertase subtilisin/kexin type 9.
Figure5 Exogenous Pcsk9 prevents SRT3025-induced increase in Ldlr expression and activity in AML12 hepatocytes. (A) Western blot and cor-
responding quantifications of AML12 cells treated with vehicle (Veh, DMSO) or 10 mM SRT3025 and incubated with or without Pcsk9 active protein
(3 ng ml21) for 1 h. (B) BODIPY-labelled LDL uptake in AML12 cells incubated for 24 h with 10 mM SRT3025 or Veh and incubated with or without
Pcsk9 active protein (3 ng ml21) for 1 h. Fluorescence intensity and western blot quantifications are given as percentage of Veh control. BODIPY,
4,4-difluoro-3a,4a-diaza-s-indacene; AU, arbitrary units; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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in LDL uptake (Figure 5B), consistent with the observed attenuation
of Ldlr protein expression (Figure 5A).
These data indicate that SRT3025 decreases hepatic Pcsk9 release,
impairs Pcsk9 binding to hepatic Ldlr, and thereby prevents hepatic
Ldlr degradation. These events result in increased hepatic Ldlr
expression and enhanced LDL-cholesterol plasma clearance.
Increased Ldlr protein expression in
AML12 hepatocytes is mediated by Sirt1
To assess whether this increase in Ldlr protein expression is
Sirt1-dependent, Sirt1 knockdown in AML12 cells was performed
in the presence of 10 mM SRT3025. In contrast to control scramble
siRNA-treated cells, cells transfected with Sirt1 siRNA did not show
an increase in Ldlr expression upon SRT3025 addition (Figure 6A).
Conversely, genetic overexpression of Sirt1 increased Ldlr protein
expression in AML12 cells compared with control transfec-
tion (Figure 6B). Thus, Sirt1 is required for SRT3025-induced in-
crease in Ldlr protein expression.
Genetic deletion of Ldlr abolishes
atheroprotective effects of SRT3025 in vivo
Given the critical role of hepatic Ldlr in the clearance of plasma
cholesterol and our observation of increased hepatic Ldlr expres-
sion in SRT3025-treated Apoe2/2 mice, we investigated whether
Ldlr accounts for the atheroprotective effects of SRT3025. For that
purpose, similar experiments were performed in Ldlr2/2 mice.
Plaque analyses of thoraco-abdominal aortae en face and cross-
sections of aortic roots revealed no difference in the extent of ath-
erosclerosis between drug- and placebo-treated mice (Figure 7A
and B). Furthermore, the number of plaque-resident macrophages
(Cd68) and Vcam-1 expression in aortic roots did not differ
between the groups (Figure 7C and D).
Plasma lipids showed an increase in total and VLDL-cholesterol
in SRT3025-treated Ldlr2/2 mice compared with placebo-treated
controls (Figure 7E and F ), whereas plasma LDL-cholesterol,
HDL-cholesterol, and triglycerides were unaffected by drug treat-
ment (Figure 7F and Supplementary material online, Figure S2A).
As in Apoe2/2 mice, SRT3025 prevented an increase in weight gain
and epididymal white adipose tissue without affecting food intake
(Supplementary material online, Figure S2B–D), and lowered plasma
levels of pro-inflammatory cytokines Mcp-1 and Il-6 (Figure 7G). Com-
pared withApoe2/2mice, baseline plasma Pcsk9 levels in Ldlr2/2mice
were about 20-fold higher (Figure 7G). SRT3025 induced a minimal but
significant increase in plasma Pcsk9 levels in Ldlr2/2 mice (Figure 7G).
Pharmacological Sirt1 activation decreased the expression of Ppara,
but did not affect Abcg5, Abcg8, Abca1, Pcsk9, Pparg, Srebp1, Srebp2,
Mcp-1 and Il-6 (Supplementary material online, Figure S2E).
Discussion
We demonstrate that pharmacological Sirt1 activation using
SRT3025 attenuated Pcsk9 secretion from murine hepatocytes in
vitro and lowered plasma levels of Pcsk9 in atherosclerosis-prone
Apoe2/2 mice in vivo. As a consequence, hepatocyte Ldlr expression
and activity were increased leading to a decrease in plasma
LDL-cholesterol and atherosclerotic plaques in Apoe2/2 mice.
None of these variables were changed in Ldlr2/2 mice despite a
similar decrease in systemic inflammation. Thus, our findings identify
reduced Pcsk9 secretion and increased Ldlr expression as novel
downstream effects of Sirt1 activity and highlight the potential
of pharmacological Sirt1 activation as a novel anti-atherosclerotic
strategy.
SRT3025 was found to activate wild-type Sirt1 protein but failed
to activate the E230K mutant, an activation-resistant Sirt1 protein
Figure 6 Sirt1 knockdown reduces and Sirt1 overexpression enhances SRT3025-induced increase in Ldlr expression in AML12 hepatocytes.
(A) Western blots of Ldlr, Sirt1, and b-actin with corresponding quantifications of AML12 cell lysates following transfection with Sirt1 siRNA or
scrambled siRNA for 24 h and incubated with 10 mM SRT3025 or vehicle (Veh, DMSO) for additional 24 h. (B) Western blots of Ldlr, Sirt1, and
b-actin with corresponding quantifications of AML12 cell lysates following Sirt1 overexpression plasmid or scramble control for 24 h and incubated
with 10 mM SRT3025 or Veh for additional 24 h. Western blot quantifications are given as a percentage of Veh control. Scr, scramble plasmid; Sirt1
OE, Sirt1 overexpression plasmid.
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(due to a mutation at position 230). Thus, similar to previously
described Sirt1 activators,15 SRT3025 acts by allosteric binding to
Sirt1 at the lysine site 230, which is located at its catalytic core. Ana-
lyses of the acetylation status of the Sirt1 target Foxo1 in skeletal
muscle and p65 in the liver show that SRT3025 increases deacetyla-
tion of Sirt1 target proteins in vivo. Furthermore, the increase in
Ldlr protein expression in AML12 cells in vitro in response to stimu-
lation with the Sirt1 activator was time- and concentration- depend-
ent and could be attenuated by knockdown of Sirt1, while genetic
Sirt1 overexpression mimicked the effects of SRT3025. These data
indicate that the SRT3025-associated changes in Ldlr expression
are Sirt1-dependent.
Endothelial-specific overexpression of Sirt1 in Apoe2/2 mice was
reported to protect against atherosclerosis by increasing endothelial
eNOS activity.2 Furthermore, using partial Sirt1 deletion in Apoe2/2
mice, we have shown that Sirt1-induced inhibition of NFkB impairs
endothelial expression of the macrophage scavenger receptor
Lox-1, and thus attenuates foam cell formation.3 Although these find-
ings address beneficial effects of Sirt1 in a particular setting of athero-
sclerosis, they provide limited insight into the effects of Sirt1 on
cholesterol metabolism. Interestingly, hepatic deletion of Sirt1 in
C57BL/6 mice fed a high-cholesterol diet was associated with a
mild increase in plasma LDL-cholesterol,7 suggesting that hepatic
Sirt1 regulates plasma LDL-cholesterol. In line with these findings,
Apoe2/2 mice treated with SRT3025 showed an increase in hepatic
Ldlr expression accompanied by a significant reduction in plasma
LDL-cholesterol levels. Moreover, the extent of aortic atheroscler-
osis and the plasma levels of LDL-cholesterol were unchanged in
Ldlr2/2 mice, highlighting the importance of Ldlr for the athero-
protective and lipid-lowering effects of Sirt1. Of note, we observed
a similar reduction in plasma levels of pro-inflammatory cytokines
in bothApoe2/2 and Ldlr2/2mice, whereas a reduction in plaque for-
mation was only observed in Apoe2/2 mice with endogenous Ldlr.
Therefore, our data suggest that not the reduction in inflammation,
which still occurs in the absence of Ldlr, but the decrease in plasma
LDL-cholesterol accounted for reducing atherosclerosis in
Apoe2/2 mice treated with SRT3025. Moreover, since we observed
a reduction in weight gain in both Apoe2/2 and Ldlr2/2 mice despite
unaltered food intake, the atherosclerotic phenotype is also inde-
pendent of changes in body weight. Taken together, we demonstrate
that the increased expression of hepatic Ldlr is essential for the
cholesterol-lowering effects of SRT3025.
In line with our findings, clinical studies with another Sirt1 ac-
tivator have shown a reduction in plasma total cholesterol and
Figure 7 Genetic deletion of Ldlr abolishes anti-atherosclerotic effects of SRT3025 in vivo. Eight-week-old Ldlr2/2 mice were fed a high-
cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n ¼ 9) or placebo (n ¼ 9) for 12 weeks and fasted for 12 h
before blood was drawn and aortae were explanted. Representative micrographs (left) and quantifications (right) of thoraco-abdominal aortae
en face (A) and of aortic root cross sections (B–D) stained with oil-red O (ORO) or immunohistochemically for macrophages (CD68) or
Vcam-1; (E) cholesterol distribution in the different lipoprotein subfractions separated by gel filtration chromatography; (F) plasma total cholesterol,
LDL-, and VLDL-cholesterol concentrations; (G) plasma levels of Mcp-1, Il-6, and Pcsk9. Scale bars in photomicrographs ¼ 1 mm (A) and 500 mm
(B–D). HCD, high-cholesterol diet; AU, arbitrary units; LDL, low-density lipoprotein; ORO, oil-red O; VLDL, very low-density lipoprotein; Vcam-1,
vascular cell adhesion molecule 1; Mcp-1, monocyte chemoattractant protein 1; Il-6, interleukin 6; Pcsk9, proprotein convertase subtilisin/kexin type 9.
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LDL-cholesterol.8,9 The presently observed reduction in VLDL-
cholesterol in mice has yet to be assessed in patients. Furthermore,
constitutive Sirt1 overexpression in Ldlr2/2 mice was associated
with increased atherosclerosis.5 Pharmacological Sirt1 activation
using an oral Sirt1 activator and constitutive genetic Sirt1overexpres-
sion are likely to differ in efficiency and may exert differential effects
on genes involved in lipid metabolism. Moreover, a difference in
NAD+ availability between both models may affect Sirt1 activity.16
It remains to be seen whether constitutive Sirt1 overexpression is
associated with enhanced hepatic expression of Ldlr in Apoe2/2
mice.
Ldlr plays a critical role in the regulation of plasma LDL-cholesterol
levels,10,11 a key determinant of atherogenesis.17 Mice overexpres-
sing hepatic Ldlr have reduced plasma LDL-cholesterol levels and
are protected from plaque formation, whereas Ldlr-deficient mice
exhibit increased levels of plasma LDL- and VLDL-cholesterol and
are prone to atherosclerosis when exposed to a high-cholesterol
diet.4,18 We show that Ldlr protein expression is increased despite
no change in Ldlr mRNA, indicating a post-translational mechanism.
Indeed, degradation of Ldlr protein in liver cells is regulated via
secreted Pcsk9, a serine protease that predominantly originates
from the liver.14,19 By binding to the EGF-A domain of Ldlr, Pcsk9
targets this receptor for lysosomal degradation rather than for recyc-
ling to the cell surface.20,21 Ldlr was reported to be the main route of
Pcsk9 clearance.22 In agreement with this, we found markedly
increased plasma Pcsk9 levels in mice lacking Ldlr.
In our study, both SRT3025 treatment and Sirt1 overexpression
increased Ldlr protein expression in AML12 cells, while reducing
the concentration of Pcsk9 in the supernatant and lowering the
amount of Pcsk9 bound to Ldlr, despite no change in Pcsk9 transcrip-
tion. Notably, exogenous addition of active Pcsk9 to AML12 cells
treated with SRT3025 decreased Ldlr protein expression and
reduced LDL uptake by the cells. These data indicate that Ldlr intern-
alization and degradation are not disrupted by SRT3025 treatment
and can be re-induced upon exogenous addition of Pcsk9. Moreover,
thesedatademonstrate that it is the limitedextracellular availabilityof
Pcsk9 that contributes to the increase in Ldlr protein expression, sug-
gesting that plasma Pcsk9 levels are an important determinant of
hepatic Ldlr protein surface expression in our model. The mechan-
isms by which Sirt1 affects Pcsk9 secretion remain to be investigated.
Yet, the specific investigation of Pcsk9-dependent alterations on ath-
erosclerosis may be hampered by reciprocal changes in Ldlr.22
Conclusions and perspectives
Our study describes a novel mechanism that causally links Sirt1 to the
metabolism of LDL-cholesterol in vitro and in vivo. We demonstrate
that Sirt1 activation increases hepatic Ldlr protein expression
through a reduction in Pcsk9-mediated Ldlr degradation leading to
decreased plaque formation.
Of note, statin therapy not only increases hepatic Ldlr, but also
plasma Pcsk9 activity, thus limiting its effect on LDL-cholesterol.23
Antibody-induced inhibition of Pcsk9 binding to Ldlr is currently
investigated as a very promising therapy to reduce plasma
LDL-cholesterol and atherosclerosis in patients.24,25 Our study
demonstrates a Sirt1-dependent alternative route to target Pcsk9 ac-
tivity in a mouse model. Thus, a Sirt1 activator combined with a statin
may confer the advantage of lowering plasma Pcsk9 activity. Future
studies are needed to translate the effects of pharmacological Sirt1
activation to patients.
Supplementary material
Supplementary material is available at European Heart Journal online.
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